Nathan D. Seligson

Nathan D. Seligson's research focuses on pediatric and adult cancers, particularly sarcomas and leukemias, combining genomic analysis with pharmacogenomics (the study of how genetic variation affects drug response) to improve cancer diagnosis and treatment. His work spans laboratory studies using CRISPR gene-editing screens to find drug targets, clinical studies on implementing genetic testing in pediatric care, and translational research on tumor immune environments and vaccines. Much of this work connects laboratory discoveries to practical clinical applications, such as guiding drug prescribing based on a patient's genetic makeup.

Publication output has grown fairly steadily over the last decade, rising from about 1 paper per year in 2017 to roughly 7-10 per year in recent years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026